Amnon Peled
About Amnon Peled
Amnon Peled, PhD (age 65), was appointed as an independent director of Silexion (SLXN) in December 2024. He is an associate professor at Hadassah Medical Center (Jerusalem) since August 2000 and served as Director of the Gene Therapy Institute at Hadassah from October 2021 to February 2024. Peled is a cytokine and hematopoietic stem cell biology expert, with 100+ publications and 200+ patents/applications; he founded Biokine Therapeutics and served as CEO/Chief Scientific Officer (advancing CXCR4 antagonist BKT140/BL8040). His education includes a BSc from Hebrew University, MSc from Tel Aviv University, PhD from the Weizmann Institute, and postdoctoral training at Harvard Medical School and the Weizmann Institute .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Hadassah Medical Center (Jerusalem) | Associate Professor | Aug 2000 – present | Focus on cytokines, stem cell biology, inflammation, cancer . |
| Gene Therapy Institute, Hadassah | Director | Oct 2021 – Feb 2024 | Led development of therapies in Phase II/III . |
| Biokine Therapeutics | Founder; CEO; Chief Scientific Officer | Jul 2000 – Feb 2024 | Advanced CXCR4 antagonist BKT140/BL8040 . |
| Harvard Medical School; Weizmann Institute | Postdoctoral training | Not disclosed | Advanced scientific credentials . |
External Roles
| Organization | Role | Status |
|---|---|---|
| Biokine Therapeutics | Founder/CEO/CSO (life sciences) | Past; through Feb 2024 . |
| Hadassah Medical Center | Associate Professor | Current . |
| Other public company boards | None disclosed in SLXN proxy/10-K | Not disclosed . |
Board Governance
- Committee assignments: Audit Committee member (chair: Dror J. Abramov; other member: Ruth Alon); Compensation Committee member (chair: Ruth Alon; other member: Dror J. Abramov); Corporate Governance & Nominating Committee member (with Dror J. Abramov, Ilan Levin, Ruth Alon) .
- Independence: Board determined Peled is an independent director under Nasdaq standards; he also meets independence standards for Audit and Compensation Committees and audit financial literacy requirements .
- Attendance: In 2024 (post-Aug 15 business combination), the Board held 7 meetings; Audit held 1; Compensation held 1; Corporate Governance & Nominating held 0; no director attended fewer than 75% of Board/committee meetings .
- Shareholder support: At the reconvened 2025 AGM (July 14, 2025), Peled’s re-election received 743,753 votes in favor (97%) and 23,361 against (3%), with 287,785 abstentions—indicating strong investor support .
2025 Director Election Vote Detail (Peled)
| Metric | Value |
|---|---|
| Votes For | 743,753 (97%) |
| Votes Against | 23,361 (3%) |
| Abstentions | 287,785 |
Fixed Compensation
| Year | Cash Retainer ($) | Committee Fees ($) | Meeting Fees ($) | Total Cash ($) |
|---|---|---|---|---|
| 2024 | — | — | — | — |
Notes: Company disclosed no cash fees paid to non-employee directors in 2024 (other than a $45,000 consulting fee to Ilan Levin) .
Performance Compensation
| Year | RSUs Granted | Grant Date | Units / Shares | Fair Value ($) | Vesting |
|---|---|---|---|---|---|
| 2024 | None disclosed for Peled | — | — | — | — |
Context: At closing of the business combination, SLXN granted 22,070 RSUs to each non-employee director that fully vested at closing; the Director Compensation table shows stock awards for several directors (e.g., $313,800), but not for Peled—consistent with his December 2024 appointment after closing .
Other Directorships & Interlocks
- No other public company directorships are disclosed in SLXN’s 2025 DEF 14A and 2024 10-K biographies for Peled .
- Private/academic roles listed above; no disclosed interlocks with SLXN competitors, suppliers, or customers in the proxy/10-K .
Expertise & Qualifications
- Scientific expertise: Cytokine research; hematopoietic stem cell biology; inflammation; cancer; therapy development; 100+ publications; 200+ patents/applications .
- Leadership: Founder/CEO/CSO of Biokine Therapeutics; led advancement of CXCR4 antagonist programs .
- Education: BSc (Hebrew University), MSc (Tel Aviv University), PhD (Weizmann Institute); postdoc training at Harvard Medical School and Weizmann .
- Financial literacy (audit committee requirement): Board determined audit members (including Peled) meet Nasdaq financial literacy standards .
Equity Ownership
| Filing | Filing Date | Transaction Date | Form | Reporting Name | Type of Owner | Direct/Indirect | Security | Securities Owned (post-txn) | SEC URL |
|---|---|---|---|---|---|---|---|---|---|
| Initial Statement of Beneficial Ownership | 2024-12-18 [SEC] | 2024-12-10 [SEC] | Form 3 [SEC] | Peled Amnon [SEC] | Director [SEC] | Direct [SEC] | Ordinary Shares [SEC] | 0 [SEC] | https://www.sec.gov/Archives/edgar/data/2022416/000117891324004002/0001178913-24-004002-index.htm |
Section 16 compliance: Based on company review and written representations, all applicable Section 16(a) filing requirements for directors were fulfilled timely for 2024 .
Governance Assessment
- Positives:
- Independent director serving on three key committees (Audit; Compensation; Corporate Governance & Nominating), meeting heightened independence and financial literacy requirements—positive for oversight robustness .
- Strong scientific credentials and drug development track record enhance domain expertise relevant to SLXN’s biotech strategy .
- High shareholder support (97% votes in favor) in 2025 director election indicates investor confidence .
- RED FLAGS / Watch items:
- Ownership alignment: Form 3 shows zero share ownership at appointment—watch for subsequent accumulation or director equity grants to improve alignment .
- 2024 director equity grant: Not disclosed for Peled while peers received fully vested RSUs at closing; monitor for future grants to align incentives .
- Committee cadence: Corporate Governance & Nominating Committee did not meet in 2024 (transitional period), which may indicate limited early-stage governance activity; ensure 2025 cadence improves .
- Conflict controls:
- Related party transactions are reviewed and approved by the Audit Committee per charter; board confirms Peled’s independence—mitigates conflict risk; no Peled-specific related-party transactions disclosed .